Skip to main content

DBV Technologies S.A.

DBVT
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001613780

In the last 90 days, DBV Technologies S.A. insiders filed 0 open-market purchases and 1 sale; 78 institutions reported holding it in 13F filings for Q2 2026, worth $345.7M in total; Duquesne Family Office is the only superinvestor holding it.

Other share classesDBVTF

Q3 2023 vs. Q2 2023

How the institutions holding DBV Technologies S.A. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of DBVT: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders3638+2
Shares46.0M44.4M−1.62M (−3.5%)
Value$87.4M$60.4M−$27.1M (−30.9%)

New holders (6)

Institutions that held DBV Technologies S.A. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to DBVT in Q3 2023
InstitutionSharesValue% of portfolio
Yiheng Capital Management, L.P.133,192$181.1K0.02%
Landscape Capital Management, L.L.C.68,911$93.7K0.01%
Tower Research Capital LLC (TRC)14,952$20.3K0.00%
XTX Topco Ltd14,426$19.6K0.00%
NBC Securities, Inc.4,000$5.00K0.00%
Cubist Systematic Strategies, LLC2,707$3.68K0.00%

Sold out (4)

Institutions that held DBV Technologies S.A. at the end of Q2 2023 and filed for Q3 2023 without it.

Institutions that sold out of DBVT in Q3 2023
InstitutionShares, Q2 2023Value, Q2 2023
Logos Global Management LP1,200,000$2.28M
Cowen and Company, LLC50,986$96.9K
Envestnet Asset Management Inc22,494$42.7K
Group One Trading, L.P.277$526